Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition

Key Terms

specific performance regulatory

A court-ordered remedy that requires a party to carry out its contractual promise instead of paying money damages. Think of it like a judge telling someone who promised to deliver a rare item to actually hand it over rather than just giving cash; for investors, it can force completion of a share sale, merger step, or asset transfer and so directly affects timing, ownership and expected value.

8-k regulatory

An 8-K is a public report companies must file with the U.S. Securities and Exchange Commission to disclose major events or changes that shareholders should know about, such as leadership changes, mergers, financial surprises, or legal developments. It matters to investors because it acts like a breaking-news alert for a company’s health and prospects—providing timely facts that can affect stock value and investment decisions.

View in glossary

10-q regulatory

A 10-Q is a company’s required quarterly filing with U.S. regulators that provides updated financial statements, management discussion of results, and disclosures about risks, legal matters and operational changes. Think of it as a quarterly report card and progress update that lets investors track recent performance, spot trends or warning signs between annual reports, and make informed buy/sell decisions based on the latest verified financial and business information.

View in glossary

sec filings regulatory

SEC filings are formal documents companies must send to the U.S. Securities and Exchange Commission that disclose key financial results, operations, risks and insider transactions. Think of them as a company’s official report card and instruction manual combined: they provide investors reliable, standardized facts used to evaluate value, spot risks, and compare companies, so missing or misleading filings can materially affect investment decisions.

View in glossary

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Complaint filed in San Diego County Superior Court seeks specific performance, alleging NRx warranted it had funds to close while concealing it lacked committed financing for the transaction.

SAN DIEGO--(BUSINESS WIRE)-- Kadima Neuropsychiatry Institute and its founder, Dr. David Feifel, have filed a complaint against NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and two of its subsidiaries in San Diego County Superior Court, alleging breach of contract and misrepresentation in connection with an acquisition agreement that the defendants warranted they had the financial capacity to close. The planned transaction represents a significant percentage of NRx’s current market capitalization.

The complaint names NRx, its subsidiary Hope Therapeutics Inc., and Hope’s subsidiary HTX Management Company LLC as defendants. It seeks specific performance in a court order compelling the defendants to close the transaction on the terms set forth in the parties’ executed agreement.

“We are confident that the evidence will demonstrate a clear pattern of intentional deceit by NRx, as it used Kadima’s and Dr. Feifel’s reputations to boost its share price through press releases and joint investor presentations, but then refused to fulfill its commitment to close the transaction,” said Andrew Selesnick, counsel to Kadima and a partner at Buchalter LLP. “Though confidentiality clauses in the agreement prohibit us from disclosing certain transaction details in a public filing, we look forward to presenting the complete set of facts in court.”

Dr. Feifel, an internationally recognized leader in the field of interventional psychiatry and professor emeritus at the University of California, San Diego, left academia to found Kadima in 2017. He has since grown it into one of California’s leading practices and research centers specializing in advanced treatments for mental health conditions.

According to the complaint, NRx Chairman Dr. Jonathan Javitt approached Dr. Feifel in 2024 with a proposal to acquire Kadima and have Dr. Feifel join Hope as Chief Medical Innovation Officer, providing repeated assurances that financing was already secured. When the parties executed an Asset Purchase and Contribution Agreement on May 9, 2025, the contract included an express representation that the purchaser had “sufficient cash on hand or other sources of immediately available funds” to close the transaction.

The complaint further notes that NRx’s January 2, 2025 press release, which announced Kadima as its planned flagship acquisition and did not reference any financing contingency, caused NRx stock to surge more than 40% in a single day. Additional press releases citing Dr. Feifel’s credentials and planned investor conference appearances followed in the months leading up to the purchase agreement execution, repeatedly boosting NRx shares.

According to the complaint, NRx’s representations regarding the availability of financing for the Kadima closing were materially inconsistent across the executed purchase agreements, its public statements, private communications, and SEC filings throughout the period leading up to and following execution of the agreement:

• Within days of signing the agreement, on May 13, 2025, Hope issued a press release announcing the signing but stating the transaction was subject to “finalization of financing.” This statement was contrary to the express terms of the agreement.
• NRx also included the same false statement in its 8-K filing with the SEC.
• After making it known it did not have the funds on hand to close, as expressed in the agreement, Hope issued a press release on May 15, 2025 stating that expected debt financing from Universal Capital would be used to finance the Kadima purchase. This also turned out to be a false statement, as it later used those funds for other acquisitions and represented in its 10-Q filing that it had “not finalized the commitment to finance” the Kadima acquisition.

The complaint also claims that to escape their obligations, Hope and HTX filed a baseless Statement of Claim against Kadima with the American Health Law Association on August 11, 2025. Less than a week later, HTX withdrew the arbitration claim just prior to the filing deadline for NRx’s mandatory 10-Q report to the SEC. This was done, the complaint notes, to avoid disclosure of material litigation to NRx’s investors as the filed 10-Q misrepresented the status of the transaction, suggesting it was proceeding. With the sanitized 10-Q filed, Hope and HTX then refiled the arbitration claim less than 10 days later.

“Kadima and Dr. Feifel performed all of their obligations under this agreement in good faith,” Selesnick said. “The agreement expressly warranted that the defendants had funds available to close. We are asking the court to hold them to that commitment.”

The case is Kadima Neuropsychiatry Institute, Medical Corp., et al. v. NRx Pharmaceuticals, Inc., et al., pending in the Superior Court of the State of California, County of San Diego — Central Division. A stamped copy of the complaint is available upon request.

About Kadima Neuropsychiatry Institute

Kadima Neuropsychiatry Institute is a leading interventional psychiatric clinic in La Jolla, California, specializing in advanced treatments and clinical research for mental health conditions. Founded by Dr. David Feifel, a pioneer in advanced psychiatric care and the physician behind the world's first clinical ketamine program for psychiatric illness, Kadima is widely respected for its clinical innovation and patient outcomes. Kadima is represented by Buchalter LLP, with offices in San Diego, Los Angeles, and multiple other cities nationwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260624388810/en/

Andrew H. Selesnick
aselesnick@buchalter.com
213.891.5223

Source: Kadima Neuropsychiatry Institute